Rigel Pharma (RIGL) Tops Q2 EPS by 4c

Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.08), $0.04 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $23.82 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight
• Delta Air shares slip despite strong outlook, Melius says